
Education

MB BCh, 6 year Medical School Program; U. of Witwatersrand, South Africa	1985-1990
Internship in Medicine, Surgery, Crit Care; Johannesburg Gnl Hospital; S. Africa	1991-1992
Senior Registrar, Thoracic & General Internal Medicine; King's College Hospital and St. Thomas Hospital London, UK.	1992-1994
Research Associate, Pulmonary, Critical Care; University of Chicago, Chicago IL	1994-1995
Categorical Residency, Internal Medicine; University of Chicago, Chicago IL	1995-1997
Research Pathway ABIM Fellowship, Pulmonary & Critical Care University of Chicago, Chicago, IL ('97-99) and Columbia U. College of Physicians & Surgeons, New York, NY; ('99-02).	1997-2002

Board Certification

American Board of Internal Medicine – Certified, Internal Medicine	1998
American Board of Internal Medicine – Certified, Pulmonary Medicine	2000
American Board of Internal Medicine – Certified, Critical Care Medicine	2001

Honors

Alpha Omega Alpha Honours Society	
The Benjamin Newman Bursary	1985 - 6
The Gencor Scholarship Prize	1989
Noristan Scholarship	1989
Washington University Traveling Scholarship (R20000)	1989
Merk Respiratory Young Investigator award	1998
Resident teacher award	1999
Junior faculty award for Resident Teaching	1999-2000
Columbia University Student Teaching award	2000
Faculty teaching award	2003
CEO Commendation Award, Denver Health Medical Center	2004 and 2006
Chest Foundation Young Leadership Award	2005

Publications

Original research and theoretical treatises:

1. Zhu X, Munoz NM, Rubio N, Herrnreiter A, Mayer D, **Douglas IS**, Leff AR Quantitation of the cytosolic phospholipase A2 (type IV) in isolated human peripheral blood eosinophils by sandwich-ELISA. *Journal of Immunological Methods*. 1996(2):119-26
2. Munoz NM, **Douglas IS**, Mayer D, Herrnreiter A, Zhu X, Leff AR Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. *Am J Respir Crit Care Med* 1997 155(4):1398-1403
3. **Douglas IS**, Leff. A, & A. Sperling, CD4+ T Cell and Eosinophil Adhesion is Mediated by Specific ICAM-3 Ligation and Results in Eosinophil Activation. *Journal of Immunology* 2000 164(6):3385-91
4. Kim JY, Park JS, Strassheim D, **Douglas IS**, Diaz del Valle F, Asehounne K, Mitra S, Kwak SH, Yamada S, Maruyama I, Ishizaka A, Abraham E. HMGB1 contributes to the development of acute lung injury after hemorrhage. *Am J Physiol Lung Cell Mol Physiol*. 2005 May;288(5):L958-65.
5. **Douglas IS**, Diaz del Valle F.; Winn RA, Voelkel, NF. β -Catenin dependent regulation of lung remodeling after oxidant – mediated injury. *Am J Respir Cell Mol Biol*. 2006 Mar;34(3):274-85.
6. Simonian PL, Roark CL, Diaz Del Valle F, Palmer BE, **Douglas IS**, Ikuta K, Born WK, O'brien RL, Fontenot AP. Regulatory Role of $\gamma\delta$ T Cells in the Recruitment of CD4+ and CD8+ T Cells to Lung and Subsequent Pulmonary Fibrosis. *J Immunol*. 2006 Oct 1;177(7):4436-43.

7. Clancy M, Graepler A, Wilson M, **Douglas IS**, Johnson J, Savor Price C. Active Screening in High-Risk Units Is an Effective and Cost-Avoidant Method to Reduce the Rate of Methicillin-Resistant Staphylococcus aureus Infection in the Hospital. *Infect Control Hosp Epidemiol* 2006;27:1009-1017.
8. O'Brien, J.M., Lu, B., Ali, N.A., Martin, G.S., Aberegg, S.K., Marsh, C.B., Lemeshow, S., **Douglas, IS**, Chronic alcohol abuse (CAA) is independently associated with sepsis, septic shock and hospital mortality among adult intensive care unit patients. (In press *Crit Care Med*)
9. Proctor G, O'Brien J. **Douglas IS**, Albert RK. The Effect of Intensivist Staffing on the Mortality of Medical Intensive Care Unit Patients (In press *Hospital Medicine*)
10. Rucker D.W., Steele A., **Douglas IS**, Couderc C., Hardel G., Multilayer Computerized Physician Order Entry Software Design to Increase Physician Expressivity, (In Press *Proc AMIA*)
11. Hoke T., **Douglas IS**, Kraskauskas D, He Z, Tao Y, Thurman J, Dursun B, Voelkel N, Edelstein C, Faubel S. Cytokine mediated pulmonary injury occurs after bilateral nephrectomy in mice. (In Press; *JASN*)
12. Bull SV, **Douglas IS**, Foster M, Albert RK. A Mandatory Protocol for Treating Adult Patients with Diabetic Ketoacidosis Decreases Intensive Care Unit and Hospital Lengths Of Stay: Results of a Nonrandomized Trial (In press; *Crit Care Med*)
13. Levi M, Levy M, Williams MD, **Douglas IS**, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundhin DP, Macias WL for the XPRESS study group. Prophylactic Heparin in Patients with Severe Sepsis Undergoing Treatment with Drotrecogin Alfa (Activated). (In review)

Nonexperimental articles:

1. **Douglas IS**, Editorial: The Plight of SA's Junior Doctors. *S Afr Med J*. 1991 6; 79(7):356
2. **Douglas IS**, White SR Should non-small cell carcinoma of the lung be treated with chemotherapy? Con: therapeutic empiricism--the case against chemotherapy in non-small cell lung cancer. *Am J Respir Crit Care Med* 1995 151(5):1288-1291
3. Schleien CL, Osmond MH, Hickey R, Hutchison J, Buunk G, **Douglas IS**, Gervais HW, Wenzel V. Postresuscitation management. *Ann Emerg Med*. 2001; 37 (4 Suppl):S182-95
4. Fessler MB, O'Brien JM, **Douglas IS**., Laboratory predictors of relative adrenal insufficiency in septic shock. *Crit Care Med*. 2003 Aug;31(8):2251-2;
5. **Douglas IS**, Possible explanations for the results of CRASH. *Lancet*. 2005 Jan 15;365(9455):212;
6. **Douglas IS**, Nicolls MR. Chemokine-mediated angiogenesis: an essential link in the evolution of airway fibrosis? *J Clin Invest*. 2005 May;115(5):1133-6
7. **Douglas IS**, Hyponatremia: why it matters, how it presents, how we can manage it. *Cleve Clin J Med*. 2006 Sep;73 Suppl 3:S4-12.
8. **Douglas IS**, Hyponatremia: A Serious Disorder? *Cleveland Clinic Journal* (In Press)
9. Arciniegas E., Frid MG, **Douglas IS**, Stenmark KR. Perspectives on Endothelial to Mesenchymal Transition: Potential Contribution to Vascular Remodeling in Chronic Pulmonary Hypertension (*Am J. Phys*, In Press)

10. Vandivier RW, Henson PM, **Douglas IS**. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. *Chest*. 2006 Jun;129(6):1673-82
11. Dexter M, Cosgrove G, **Douglas IS**. Cases from UCHSC: Respiratory Failure In Pulmonary Alveolar Proteinosis. *Chest* (In Press)
12. Taraseviciene-Stewart L, **Douglas IS**, Nana-Sinkam PS, Lee JD, Tuder RM, Nicolls MR, Voelkel NF. Is alveolar destruction and emphysema in COPD an immune disease? *Proc. Am. Thoracic Soc.*, (In Press)
13. Henson PM, **Douglas IS**. Cell death, remodeling and repair in COPD. *Proc. Am. Thoracic Soc.*, (In Press)
14. Voelkel NF, **Douglas IS**, Nicolls MR. Angiogenesis in Chronic Lung Diseases. Invited Review CHEST (In review)

Book Chapters:

1. **Douglas IS**, Hamman K. Eosinophil mediators; Chapter in *Asthma and Rhinitis*, 2nd Ed. Stephen Holgate, W. W. Busse. Blackwell Science. 2000.
2. **Douglas IS**. Torso Trauma; Chapter in *Principles of Critical Care Handbook*; 2nd Ed. Jesse B. Hall, Gregory A. Schmidt, Lawrence D. H. Wood; McGraw-Hill, 2000
3. **Douglas IS**. Ischemic Heart Disease and Thrombolytic Therapy; Chapter in *Principles of Critical Care Handbook*; 2nd Ed. Jesse B. Hall, Gregory Schmidt, Lawrence Wood; McGraw-Hill, 2000
4. **Douglas IS**. The Yin and yang of critical care – Utilitarianism meets the law of supply and demand; *International Perspectives on Critical Care*; David Crippen Ed. 2002
5. **Douglas IS**, Schmidt G. Acute Right Heart Syndrome; Chapter in *Principles of Critical Care*; 3rd Ed. Jesse B. Hall, Gregory A. Schmidt, Lawrence D. H. Wood; McGraw-Hill; 2005;
6. **Douglas IS**, Schmidt G. Hall J. Acute on Chronic Respiratory Failure; *Ibid*.

Funded Research

2003 – 2008 NHLBI, NIH – 1-K08 HL0770940

Angiogenesis in Hyperoxic Lung Fibrosis – Role: Principal Investigator; K08 Career Award

2005-2008 NIH SCCOR HL073994

Ventilator associated lung injury: Molecular approaches”. Role: Co-Principal Investigator; Principal Investigator; JG Garcia, J Maloney

2005 – 2010 NHLBI N01-HR-56167

Critical Care Treatment Group (CCTG) for a Clinical Network for the Treatment of Adult Respiratory Distress Syndrome (ARDS) – Role: Co-Principal Investigator; Principal Investigator: M. Moss.

2005-2006 Dept. of Medicine, UCDHSC Small Grants Program

A Randomized Prospective Pilot Study Of Haloperidol In Addition To Standard Sedation In Mechanically Ventilated Patients With Delirium

2006 - 2007 Eli Lilly & Co.

F1K-MC-EVDA: An Evaluation Of Vasopressor Requirement, Hemodynamic Response And Measures Of Tissue Perfusion With The Administration Of Drotrecogin Alfa (Activated) As Part Of Physician-Directed Therapy In Patients With Septic Shock – Principal Investigator

2003 –2005 Johnson and Johnson; OrthoBitech
EPO – ICU-002: A Randomized, Double-Blind, Placebo Controlled Study To Determine The Efficacy And Safety Of Epoetin Alfa In Critically Ill Subjects – Principal Investigator, Enrollment complete

2006 – 2008 Amgen
AMGEN 20041919: A Prospective Study to Evaluate the Erythropoietic Responsiveness Associated with Once Weekly Administration of Darbepoetin Alfa (Aranesp) in Patients Admitted to the Intensive Care Unit – Principal Investigator

2005 – 2007 Hospira
A Phase 4, Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater than Twenty-Four Hours of Continuous Sedation; Hospira 2001-001 – Principal Investigator.

2005 – 2007 C.R. Bard Inc.
Multi-Center Clinical Study Of The Bard Silver-Coated Endotracheal Tube To Reduce Ventilator Associated Pneumonia (VAP) - BISCETT – Principal Investigator.

2005 – 2006 Nostix LLC,
Non-Invasive Glucose Monitor Testing Using the Critical Care Monitor in Subjects With Type 1 Diabetes Or Type 2 Diabetes – Principal Investigator.